Aa
VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid
I know some people don't like the vx-950 posts. This is really to good not to post.
New data announced today by Vertex Pharmaceuticals Incorporated VRTX show that VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor, dosed in combination with pegylated interferon alfa-2a (Pegasys(R); peg-IFN), achieved a rapid and dramatic reduction in plasma viral RNA levels in patients with chronic genotype 1 HCV infection. In this Phase Ib study, the combination of VX-950 and peg-IFN produced an initial median reduction in plasma HCV RNA of more than 3 log10 in the first two days, followed by continued decline to a median 5.5 log10 reduction in HCV RNA at day 14, which equates to a 300,000- fold reduction in viral levels. The majority of patients (6 of 8) receiving the combination achieved HCV RNA levels below the limit of quantitation (30 IU/mL, as measured by the Roche TaqMan(R) assay) at 14 days, with 4 of 8 patients achieving HCV RNA levels below the limit of detection (10 IU/mL, Roche TaqMan(R)). The antiviral activity of the combination through 14 days was significantly greater than the activity of VX-950 administered as a single agent, and much greater than peg-IFN alone. In addition, VX-950 appeared to be well-tolerated when dosed alone and in combination with peg-IFN in the study. The full data set will be presented at a medical conference later this year.
There is more to this story. Only allowed 1600 Characters. They do go on to say they are looking at only 3 Months for treatment. That has got to be good news.
New data announced today by Vertex Pharmaceuticals Incorporated VRTX show that VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor, dosed in combination with pegylated interferon alfa-2a (Pegasys(R); peg-IFN), achieved a rapid and dramatic reduction in plasma viral RNA levels in patients with chronic genotype 1 HCV infection. In this Phase Ib study, the combination of VX-950 and peg-IFN produced an initial median reduction in plasma HCV RNA of more than 3 log10 in the first two days, followed by continued decline to a median 5.5 log10 reduction in HCV RNA at day 14, which equates to a 300,000- fold reduction in viral levels. The majority of patients (6 of 8) receiving the combination achieved HCV RNA levels below the limit of quantitation (30 IU/mL, as measured by the Roche TaqMan(R) assay) at 14 days, with 4 of 8 patients achieving HCV RNA levels below the limit of detection (10 IU/mL, Roche TaqMan(R)). The antiviral activity of the combination through 14 days was significantly greater than the activity of VX-950 administered as a single agent, and much greater than peg-IFN alone. In addition, VX-950 appeared to be well-tolerated when dosed alone and in combination with peg-IFN in the study. The full data set will be presented at a medical conference later this year.
There is more to this story. Only allowed 1600 Characters. They do go on to say they are looking at only 3 Months for treatment. That has got to be good news.
This is new news today. The old news was just with vx-950. This is with peg and vx-950. The Europe trials. If you want to read the whole thing go to http://news.moneycentral.msn.com/ticker/article.asp?Feed=PR&Date=20060109&ID=5400140&Symbol=US:VRTX
Ron
Ron
I'll pop on my sopbox for just a sec here, then hop off. Thanks for indulging me.
Cuteus: I'm basing my comments from memory. This is combo therapy this time. I belive VX-950 mono-therapy gave about a mean 4.5 L drop in 2 weeks. Combo with INF raised that to 5.5 L, a full log above VX-950 mono - in two weeks. Compare that to SOC where our target is overall 2 log total in 12 weeks.
-------------------------------------------------------------
Andy: "The 2-week period was completed quite some time ago. How come no info since them? Rebound? Rapid resistance?"
<b>NOBODY</b> discloses the data that VRTX does. VRTX was under no obligation to disclose the rebounds they encountered in sub-otimal dosing before - yet they did. In fact, they published patient level detail for every arm of the study. Yet you imply they hide something. Of course, you offer no evidence that they have hidden anything. Just whispers from your secret sources in the pharm industry - well I'll admit, your anti-VRTX bias sure does reek of ties to secret sources in the pharm industry.
"Also on the horizon with much better data from a ongoing phase IIb trial without the thrombocytopenia and neutropenia safety issues VX950 has shown."
No kidding? Please post references.
Cuteus: I'm basing my comments from memory. This is combo therapy this time. I belive VX-950 mono-therapy gave about a mean 4.5 L drop in 2 weeks. Combo with INF raised that to 5.5 L, a full log above VX-950 mono - in two weeks. Compare that to SOC where our target is overall 2 log total in 12 weeks.
-------------------------------------------------------------
Andy: "The 2-week period was completed quite some time ago. How come no info since them? Rebound? Rapid resistance?"
<b>NOBODY</b> discloses the data that VRTX does. VRTX was under no obligation to disclose the rebounds they encountered in sub-otimal dosing before - yet they did. In fact, they published patient level detail for every arm of the study. Yet you imply they hide something. Of course, you offer no evidence that they have hidden anything. Just whispers from your secret sources in the pharm industry - well I'll admit, your anti-VRTX bias sure does reek of ties to secret sources in the pharm industry.
"Also on the horizon with much better data from a ongoing phase IIb trial without the thrombocytopenia and neutropenia safety issues VX950 has shown."
No kidding? Please post references.
sounds right to me. your memory is holding. I just like to see true balance.
So the IFN helped a little? looks like combo therapy without the "benefit" of riba. Still, too soon to tell.
I'll try not to pull my hair again next time a vx thread is started, which should be in about 48 hrs. ;-}
TY
So the IFN helped a little? looks like combo therapy without the "benefit" of riba. Still, too soon to tell.
I'll try not to pull my hair again next time a vx thread is started, which should be in about 48 hrs. ;-}
TY
Fallacy of the Assumed but Hidden Truth: To assume that a conspiracy is in place to guard a hidden truth which would devastate the conspirators if it got out? This is fallacious as it is not substantiated.
Your comment
Your comment
"I do predict that this stock will go either up, down or remain the same"
lol, I can predict that too!
the rest, I can't touch it! It is still floating over my head...
lol, I can predict that too!
the rest, I can't touch it! It is still floating over my head...
cuteus: So the IFN helped a little?
Well, if you call 1 log in 2 weeks 'a little', then yeah, I suppose so. Hey maybe it's the VX-950 threads that are causing my hair to thin?
Andy: Sorry - couldn't make it through your post. FYI, my interest here is watching for a cure for HCV, I don't care about VRTX share price anymore than I do whether gas goes up or down a nickle a gallon. If another PI shows more promise, I'll be more happy.
Well, if you call 1 log in 2 weeks 'a little', then yeah, I suppose so. Hey maybe it's the VX-950 threads that are causing my hair to thin?
Andy: Sorry - couldn't make it through your post. FYI, my interest here is watching for a cure for HCV, I don't care about VRTX share price anymore than I do whether gas goes up or down a nickle a gallon. If another PI shows more promise, I'll be more happy.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
